Drugs / VV-14295
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06765980 | May 2025 → Dec 2027 expected | age-related macular degeneration | Kriya Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VV-14295 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06765980 ↗ |
| Known as | KRIYA-825 | “KRIYA-825 (VV-14295)” NCT06765980 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “Adeno-associated Virus Vector VV-14295” NCT06765980 ↗ |
| Route | Other | “VV-14295 will be administered as a single suprachoroidal injection.” NCT06765980 ↗ |